Analysis of possible side effects when using Bortezomib

Bortezomib is an important proteasome inhibitor and is widely used in the treatment of multiple myeloma and certain lymphomas. It inhibits the proteasome function in tumor cells, blocks the protein degradation process, induces tumor cell apoptosis, and significantly improves the therapeutic effect of patients. However, the use of bortezomib may be accompanied by a variety of side effects. Understanding these side effects and their countermeasures is crucial to ensuring the patient's treatment safety and quality of life.

Neuropathy is the most common and representative side effect of bortezomib. Patients may experience symptoms such as numbness, tingling, burning, and hypoesthesia in their hands and feet during medication. This type of peripheral neuropathy mostly involves sensory nerves, and may affect motor function in severe cases. Its mechanism is mainly related to nerve cell damage caused by proteasome inhibition. In order to reduce neuropathy, doctors will adjust the dosage or extend the dosage interval according to the patient's symptoms, and suspend the medication if necessary. In addition, auxiliary treatments such as vitamin BB supplementation and antioxidants can also help relieve symptoms.

Adverse reactions to the digestive system are common, including nausea, vomiting, diarrhea, constipation, and loss of appetite. These side effects are mostly mild to moderate and can usually be alleviated by adjusting your diet, taking anti-nausea medications, and staying hydrated. For severe gastrointestinal reactions, temporary drug discontinuation or dose reduction may be necessary to prevent complications such as malnutrition and dehydration.

In terms of blood system, bortezomib may cause thrombocytopenia, leukopenia and anemia, increasing the patient's risk of infection and bleeding. Regular monitoring of blood routine is necessary. Once a significant decrease in blood cells is found, the treatment plan should be adjusted in time, and growth factor support or blood transfusion should be given if necessary. Patients should pay attention to preventing infection, maintaining good personal hygiene, and avoiding contact with sources of infection.

In addition, bortezomib may also cause cardiotoxicity, abnormal liver function, injection site reactions, and fatigue. Although cardiotoxicity is rare, patients with a history of heart disease need special attention, and regular heart function tests are particularly important. Liver function abnormalities are generally reversible. When they occur, liver function indicators should be monitored and medications adjusted as appropriate. Redness, swelling, and pain may occur at the injection site, which is usually a mild reaction that can be relieved with cold compresses and local care. Fatigue is caused by many factors, and patients should arrange rest and activities reasonably.

In general, although bortezomib has significant anti-tumor activity, its side effects are diverse and may affect patients' quality of life. Through early identification and active intervention, and reasonable adjustment of medication dosage and treatment regimen, most side effects can be controlled. Patients should closely cooperate with their doctors during medication, report abnormal symptoms in a timely manner, and maintain good living habits and nutritional support to ensure the smooth progress of treatment and the realization of maximum efficacy.

Reference materials:https://www.drugs.com